Best in Biotech 18 May 2023
Six women’s health companies you should know about
While sexism exists in all strands of society, where in 2023, women earn 77 cents for every dollar earned by men, studies estimate that it will take the world 257…
ObsEva
- Latest Posts
More News! 10 Dec 2019
ObsEva’s Oral Treatment for Uterine Fibroids Nails Phase III
An oral drug developed by the Swiss company ObsEva was shown to reduce menstrual bleeding and pain caused by uterine fibroids. The phase III trial tested ObsEva’s drug candidate linzagolix…
News and Trends 27 Feb 2018
Successful Phase III Results for Swiss Biotech ObsEva’s Drug for In Vitro Pregnancy
Yesterday, Swiss biotech ObsEva highlighted positive Phase III results that show their fertility treatment nolasiban improved the pregnancy rate of women following in vitro fertilization. ObsEva, a clinical stage, Geneva-based biopharmaceutical…
Interview 26 Jun 2017
Meet the Gynecologist at the Helm of Geneva’s Star Biotech
Ernest Loumaye began as a doctor at a university hospital and is now CEO of ObsEva. We chatted about how biotech supports women’s health. ObsEva, one of the top biotechs…
ADVERTISEMENT
Best in Biotech 30 May 2017
In Geneva, the Capital of Peace, 10 Biotechs Are Putting up a Fight
Geneva is the largest city in French-speaking Switzerland, a financial powerhouse, home to the United Nations and known as the "Peace Capital." Can the city's biotech industry justify its high profile?…
More News! 7 Mar 2017
UPDATE: Reproductive Health Biotech starts Phase III after €90M IPO
UPDATE (07/03/2017): ObsEva has announced the start of its Phase III trials for nolasiban, an oral oxytocin receptor antagonist. It is under evaluation for improvements in pregnancy and live birth rates following embryo…
